{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,6]],"date-time":"2026-06-06T00:45:34Z","timestamp":1780706734481,"version":"3.54.1"},"reference-count":63,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002784","name":"Canada Excellence Research Chairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002784","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001804","name":"Canada Research Chairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["canadianjournalofdiabetes.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Diabetes"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jcjd.2025.10.175","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:08:57Z","timestamp":1761869337000},"page":"38-46.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Semaglutide Use With Automated Insulin Delivery in Adults With Type 1 Diabetes: Qualitative Analyses and Patient-reported Outcomes From a Randomized Controlled Trial"],"prefix":"10.1016","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2389-9066","authenticated-orcid":false,"given":"Melissa-Rosina","family":"Pasqua","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7349-1430","authenticated-orcid":false,"given":"Joelle","family":"Doumat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8326-7274","authenticated-orcid":false,"given":"Michael A.","family":"Tsoukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Haidar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjd.2025.10.175_bib1","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1210\/endrev\/bnac022","article-title":"Consensus recommendations for the use of automated insulin delivery technologies in clinical practice","volume":"44","author":"Phillip","year":"2023","journal-title":"Endocr Rev"},{"key":"10.1016\/j.jcjd.2025.10.175_bib2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jcjd.2025.01.001","article-title":"Glycemic management across the lifespan for people with type 1 diabetes: A clinical practice guideline","volume":"49","author":"Halperin","year":"2025","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.jcjd.2025.10.175_bib3","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1089\/dia.2019.0400","article-title":"Prospective analysis of the impact of commercialized hybrid closed-loop system on glycemic control, glycemic variability, and patient-related outcomes in children and adults: A focus on superiority over predictive low-glucose suspend technology","volume":"22","author":"Beato-V\u00edbora","year":"2020","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.jcjd.2025.10.175_bib4","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1089\/dia.2020.0388","article-title":"Real-world patient-reported outcomes and glycemic results with initiation of Control-IQ technology","volume":"23","author":"Pinsker","year":"2021","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.jcjd.2025.10.175_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2022.109998","article-title":"How introduction of automated insulin delivery systems may influence psychosocial outcomes in adults with type 1 diabetes: Findings from the first investigation with the Omnipod\u00ae 5 system","volume":"190","author":"Polonsky","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jcjd.2025.10.175_bib6","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/dom.13052","article-title":"The challenges of achieving postprandial glucose control using closed-loop systems in patients with type 1 diabetes","volume":"20","author":"Gingras","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jcjd.2025.10.175_bib7","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1177\/19322968211035411","article-title":"Strategically playing with fire: SGLT inhibitors as possible adjunct to closed-loop insulin therapy","volume":"15","author":"Pasqua","year":"2021","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.jcjd.2025.10.175_bib8","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/pedi.12166","article-title":"A decade of temporal trends in overweight\/obesity in youth with type 1 diabetes after the diabetes control and complications trial (DCCT)","volume":"16","author":"Baskaran","year":"2015","journal-title":"Pediatr Diabetes"},{"key":"10.1016\/j.jcjd.2025.10.175_bib9","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1464-5491.2010.02956.x","article-title":"Temporal patterns in overweight and obesity in Type 1 diabetes","volume":"27","author":"Conway","year":"2010","journal-title":"Diabet Med"},{"key":"10.1016\/j.jcjd.2025.10.175_bib10","doi-asserted-by":"crossref","first-page":"707","DOI":"10.2337\/dc06-1982","article-title":"Insulin resistance, the metabolic syndrome, and complication risk in type 1 diabetes: \u2018Double diabetes\u2019 in the diabetes control and complications trial","volume":"30","author":"Kilpatrick","year":"2007","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcjd.2025.10.175_bib11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s40608-018-0193-5","article-title":"Abdominal obesity in type 1 diabetes associated with gender, cardiovascular risk factors and complications, and difficulties achieving treatment targets: A cross sectional study at a secondary care diabetes clinic","volume":"5","author":"Melin","year":"2018","journal-title":"BMC Obes"},{"key":"10.1016\/j.jcjd.2025.10.175_bib12","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1089\/dia.2019.0027","article-title":"Adjunct therapy in type 1 diabetes: A survey to uncover unmet needs and patient preferences beyond HbA1c measures","volume":"21","author":"Pettus","year":"2019","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.jcjd.2025.10.175_bib13","first-page":"1","article-title":"Can unmet needs be addressed by adjunctive therapies? Findings from a patient perspectives survey in adults with type 1 diabetes","volume":"11","author":"Lamaro","year":"2024","journal-title":"J Patient Experiences"},{"key":"10.1016\/j.jcjd.2025.10.175_bib14","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1177\/19322968231176302","article-title":"Participant experiences of low-dose empagliflozin use as adjunct therapy to hybrid closed-loop: Findings from a randomized controlled trial","volume":"17","author":"Pasqua","year":"2023","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.jcjd.2025.10.175_bib15","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jcjd.2020.08.002","article-title":"Pharmacologic glycemic management of type 2 diabetes in adults: 2020 update---the user\u2019s guide","volume":"44","author":"Senior","year":"2020","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.jcjd.2025.10.175_bib16","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcjd.2025.10.175_bib17","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","article-title":"Once-weekly semaglutide in adults with overweight or obesity","volume":"384","author":"Wilding","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcjd.2025.10.175_bib18","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcjd.2025.10.175_bib19","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcjd.2025.10.175_bib20","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jcjd.2025.10.175_bib21","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.2337\/dc16-0691","article-title":"Efficacy and safety of liraglutide added to insulin treatment in type 1 diabetes: The adjunct one treat-to-target randomized trial","volume":"39","author":"Mathieu","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcjd.2025.10.175_bib22","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.2337\/dc16-0690","article-title":"Efficacy and safety of liraglutide added to capped insulin treatment in subjects with type 1 diabetes: The adjunct two randomized trial","volume":"39","author":"Ahren","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcjd.2025.10.175_bib23","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/dom.13911","article-title":"Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: The Lira Pump trial---a randomized, double-blinded, placebo-controlled trial","volume":"22","author":"Dejgaard","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jcjd.2025.10.175_bib24","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1111\/dom.14090","article-title":"Liraglutide treatment in overweight and obese patients with type 1 diabetes: A 26-week randomized controlled trial; mechanisms of weight loss","volume":"22","author":"Ghanim","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jcjd.2025.10.175_bib25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/jama.2024.18581","article-title":"GLP-1 receptor agonist and SGLT2 inhibitor prescribing in people with type 1 diabetes","volume":"332","author":"Li","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jcjd.2025.10.175_bib26","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2337\/dc10-1343","article-title":"Psychometric properties of the hypoglycemia fear survey-II for adults with type 1 diabetes","volume":"34","author":"Gonder-Frederick","year":"2011","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcjd.2025.10.175_bib27","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/j.jdiacomp.2015.01.012","article-title":"Understanding the sources of diabetes distress in adults with type 1 diabetes","volume":"29","author":"Fisher","year":"2015","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.jcjd.2025.10.175_bib28","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1046\/j.1365-2036.2003.01553.x","article-title":"Development and validation of the diabetes bowel symptom questionnaire","volume":"17","author":"Quan","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.jcjd.2025.10.175_bib29","doi-asserted-by":"crossref","first-page":"51","DOI":"10.2337\/dc08-0856","article-title":"Diabetes medication satisfaction tool","volume":"32","author":"Anderson","year":"2009","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcjd.2025.10.175_bib30","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/dme.13930","article-title":"Assessing patient-reported outcomes for automated insulin delivery systems: The psychometric properties of the INSPIRE measures","volume":"36","author":"Weissberg-Benchell","year":"2019","journal-title":"Diabet Med"},{"key":"10.1016\/j.jcjd.2025.10.175_bib31","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1089\/dia.2017.0007","article-title":"It is definitely a game changer: A qualitative study of experiences with in-home overnight closed-loop technology among adults with type 1 diabetes","volume":"19","author":"Hendrieckx","year":"2017","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.jcjd.2025.10.175_bib32","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1177\/1932296817702656","article-title":"Closing the loop in adults, children and adolescents with suboptimally controlled type 1 diabetes under free living conditions: A psychosocial substudy","volume":"11","author":"Barnard","year":"2017","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.jcjd.2025.10.175_bib33","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1111\/j.1464-5491.2010.03061.x","article-title":"Psychosocial factors associated with use of continuous glucose monitoring","volume":"27","author":"Ritholz","year":"2010","journal-title":"Diabet Med"},{"key":"10.1016\/j.jcjd.2025.10.175_bib34","series-title":"Swedish diabetes patients\u2019 experiences of using GLP-1 receptor agonists (GLP-1 RAs)","author":"Ekenberg","year":"2020"},{"key":"10.1016\/j.jcjd.2025.10.175_bib35","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s41591-024-03463-z","article-title":"Subcutaneous weekly semaglutide with automated insulin delivery in type 1 diabetes: A double-blind, randomized, crossover trial","volume":"31","author":"Pasqua","year":"2025","journal-title":"Nat Med"},{"key":"10.1016\/j.jcjd.2025.10.175_bib36","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2337\/dc22-0490","article-title":"Low-dose empagliflozin as adjunct to hybrid closed-loop insulin therapy in adults with suboptimally controlled type 1 diabetes: A randomized crossover controlled trial","volume":"46","author":"Pasqua","year":"2023","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcjd.2025.10.175_bib38","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jdiacomp.2016.03.032","article-title":"Diabetes distress in adults with type 1 diabetes: Prevalence, incidence and change over time","volume":"30","author":"Fisher","year":"2016","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.jcjd.2025.10.175_bib39","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3390\/ijerph15050947","article-title":"Use of diabetes treatment satisfaction questionnaire in diabetes care: Importance of patient-reported outcomes","volume":"15","author":"Saisho","year":"2018","journal-title":"Int J Environ Res Public Health"},{"key":"10.1016\/j.jcjd.2025.10.175_bib40","doi-asserted-by":"crossref","first-page":"e489","DOI":"10.1016\/S2589-7500(24)00092-X","article-title":"Simple meal announcements and pramlintide delivery versus carbohydrate counting in type 1 diabetes with automated fast-acting insulin aspart delivery: A randomised crossover trial in Montreal, Canada","volume":"6","author":"Cohen","year":"2024","journal-title":"Lancet Digit Health"},{"key":"10.1016\/j.jcjd.2025.10.175_bib41","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1007\/s12020-024-03760-0","article-title":"Diabetes distress and diabetes burnout explored in various areas of life in patients with type 1 diabetes: Effect of short-term psychological intervention","volume":"85","author":"Cyranka","year":"2024","journal-title":"Endocrine"},{"key":"10.1016\/j.jcjd.2025.10.175_bib42","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1089\/dia.2021.0089","article-title":"Patient-reported outcomes in a randomized trial of closed-loop control: The Pivotal International Diabetes Closed-Loop Trial","volume":"23","author":"Kudva","year":"2021","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.jcjd.2025.10.175_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102119","article-title":"Effect of diabetes technologies on the fear of hypoglycaemia among people living with type 1 diabetes: A systematic review and meta-analysis","volume":"62","author":"Talbo","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jcjd.2025.10.175_bib44","first-page":"1","article-title":"Automated insulin delivery during the first 6 months postpartum (AiDAPT): A prespecified extension study","volume":"8587","author":"Lee","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.jcjd.2025.10.175_bib45","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1089\/dia.2023.0490","article-title":"Efficacy of semaglutide in overweight and obese patients with type 1 diabetes","volume":"26","author":"Garg","year":"2024","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.jcjd.2025.10.175_bib46","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2337\/ds20-0025","article-title":"Exploring why people with type 2 diabetes do or do not persist with glucagon-like peptide-1 receptor agonist therapy: A qualitative study","volume":"34","author":"Polonsky","year":"2021","journal-title":"Diabetes Spectrum"},{"key":"10.1016\/j.jcjd.2025.10.175_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/20420188231180987","article-title":"Patient-perceived benefits and risks of off-label use of SGLT2 inhibitors and GLP-1 receptor agonists in type 1 diabetes: A structured qualitative assessment","volume":"14","author":"Edwards","year":"2023","journal-title":"Ther Adv Endocrinol Metab"},{"key":"10.1016\/j.jcjd.2025.10.175_bib48","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1001\/jama.2023.2438","article-title":"As Ozempic\u2019s popularity soars, here\u2019s what to know about semaglutide and weight loss","volume":"329","author":"Suran","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jcjd.2025.10.175_bib49","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00125-019-05065-8","article-title":"Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: A substudy of the SUSTAIN 8 randomised controlled clinical trial","volume":"63","author":"McCrimmon","year":"2020","journal-title":"Diabetologia"},{"issue":"Suppl. 1","key":"10.1016\/j.jcjd.2025.10.175_bib50","doi-asserted-by":"crossref","first-page":"A16","DOI":"10.1210\/jendso\/bvab048.030","article-title":"Impact of semaglutide on body composition in adults with overweight or obesity: Exploratory analysis of the STEP 1 study","volume":"5","author":"Wilding","year":"2021","journal-title":"J Endocr Soc"},{"key":"10.1016\/j.jcjd.2025.10.175_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jdiacomp.2024.108689","article-title":"Delayed prandial insulin boluses are an important determinant of blood glucose control and relate to fear of hypoglycemia in people with type 1 diabetes on advanced technologies","volume":"38","author":"Annuzzi","year":"2024","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.jcjd.2025.10.175_bib52","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1089\/dia.2024.0022","article-title":"Impact of missed and late meal boluses on glycemic outcomes in automated insulin delivery-treated children and adolescents with type 1 diabetes: A two-center, population-based, cohort study","volume":"26","author":"Laugesen","year":"2024","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.jcjd.2025.10.175_bib53","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1089\/dia.2022.0518","article-title":"Hybrid closed loop overcomes the impact of missed or suboptimal meal boluses on glucose control in children with type 1 diabetes compared to sensor-augmented pump therapy","volume":"25","author":"Coutant","year":"2023","journal-title":"Diabetes Technol Ther"},{"key":"10.1016\/j.jcjd.2025.10.175_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmpb.2020.105416","article-title":"Glucose outcomes of a learning-type artificial pancreas with an unannounced meal in type 1 diabetes","volume":"191","author":"Song","year":"2020","journal-title":"Comput Methods Programs Biomed"},{"key":"10.1016\/j.jcjd.2025.10.175_bib55","doi-asserted-by":"crossref","first-page":"2090","DOI":"10.1111\/dom.14447","article-title":"Alleviating carbohydrate counting with a FiASP-plus-pramlintide closed-loop delivery system (artificial pancreas): Feasibility and pilot studies","volume":"23","author":"Tsoukas","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jcjd.2025.10.175_bib56","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2337\/dc19-0895","article-title":"Faster compared with standard insulin aspart during day-and-night fully closed-loop insulin therapy in type 1 diabetes: A double-blind randomized crossover trial","volume":"43","author":"Dovc","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcjd.2025.10.175_bib57","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1111\/dom.14258","article-title":"Add-on therapy with dapagliflozin under full closed loop control improves time in range in adolescents and young adults with type 1 diabetes: The DAPADream study","volume":"23","author":"Biester","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"Suppl. 1","key":"10.1016\/j.jcjd.2025.10.175_bib58","first-page":"1","article-title":"60-OR: A pilot study evaluating an insulin and pramlintide fully closed-loop delivery system","volume":"72","author":"Odabassian","year":"2023","journal-title":"Diabetes"},{"key":"10.1016\/j.jcjd.2025.10.175_bib59","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1016\/S2589-7500(24)00002-5","article-title":"Bihormonal fully closed-loop system for the treatment of type 1 diabetes: A real-world multicentre, prospective, single-arm trial in the Netherlands","volume":"6","author":"van Bon","year":"2024","journal-title":"Lancet Digit Health [Internet]"},{"key":"10.1016\/j.jcjd.2025.10.175_bib60","doi-asserted-by":"crossref","first-page":"836","DOI":"10.2337\/dc20-2106","article-title":"Fully closed loop glucose control with a bihormonal artificial pancreas in adults with type 1 diabetes: An outpatient, randomized, crossover trial","volume":"44","author":"Blauw","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcjd.2025.10.175_bib61","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.2337\/dc16-0089","article-title":"Mitigating meal-related glycemic excursions in an insulin-sparing manner during closed-loop insulin delivery: The beneficial effects of adjunctive pramlintide and liraglutide","volume":"39","author":"Sherr","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jcjd.2025.10.175_bib62","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1177\/1932296814542153","article-title":"Role of glucagon-like peptide-1 analogue versus Amylin as an adjuvant therapy in type 1 diabetes in a closed loop setting with ePID algorithm","volume":"8","author":"Renukuntla","year":"2014","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.jcjd.2025.10.175_bib63","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1177\/1932296816647976","article-title":"Adjuvant liraglutide and insulin versus insulin monotherapy in the closed-loop system in type 1 diabetes: A randomized open-labeled crossover design trial","volume":"10","author":"Ilkowitz","year":"2016","journal-title":"J Diabetes Sci Technol"},{"key":"10.1016\/j.jcjd.2025.10.175_bib64","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/1477-7525-5-57","article-title":"The Diabetes Treatment Satisfaction Questionnaire change version (DTSQc) evaluated in insulin glargine trials shows greater responsiveness to improvements than the original DTSQ","volume":"5","author":"Bradley","year":"2007","journal-title":"Health Qual Life Outcomes"}],"container-title":["Canadian Journal of Diabetes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499267125003673?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1499267125003673?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T20:54:05Z","timestamp":1770929645000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1499267125003673"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1499267125003673"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjd.2025.10.175","relation":{},"ISSN":["1499-2671"],"issn-type":[{"value":"1499-2671","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Semaglutide Use With Automated Insulin Delivery in Adults With Type 1 Diabetes: Qualitative Analyses and Patient-reported Outcomes From a Randomized Controlled Trial","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Diabetes","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjd.2025.10.175","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Diabetes Canada.","name":"copyright","label":"Copyright"}]}}